Now that the service economy is pretty much stopped in its tracks, here are promising areas, including technology as manufacturing, to consider.
While Johnson & Johnson and other pharma cos. give us hope, here's my wish list to keep the nation safe and the economy ready to go again.
Our technical strategy says that Eli Lilly can be bought on strength over $144, as the name looks more attractive along with others in the health care sector.
As it gets the OK for a new rapid Covid-19 detecting device, Abbott Labs could be purchased here following our new technical strategy.
While the short-term picture of JNJ suggests more risk is possible, the longer-term patterns are constructive.
Japan is a leader in pharmaceuticals and has three companies working overtime to develop treatments for Covid-19.
I do believe that having no economy is temporary. I also believe that what comes out on the other side will be smaller, far less global.
The drug and vaccine maker possibly could see its shares double according to a key chart.
These pharmaceutical names have what it takes amid the current crisis and for the long run.
A strong S&P for three days makes me leery of what's ahead, but here's an option in JNJ.